Canopy Growth (WEED) Stock Price, News & Analysis

Company Overview

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; and partnership with Parent Action on Drugs. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Key Stats

• Today's Range: C$6.19 to C$6.42
• 50-Day Range: C$6.07 to C$11.44
• 52-Week Range: C$3.74 to C$20.50
• Volume: 879,829 shs
• Average Volume: 2.15 million shs
• Market Capitalization: C$538.86 million
• P/E Ratio: N/A
• Dividend Yield: 4.80%
• Price Target: C$7.12
• Consensus Rating: Reduce

Canopy Growth Stock Analysis - MarketRank™

Canopy Growth scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Canopy Growth has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 2 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Canopy Growth has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Canopy Growth is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Canopy Growth is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Canopy Growth, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Canopy Growth has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for WEED.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Canopy Growth is a leading dividend payer. It pays a dividend yield of 4.80%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Canopy Growth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for WEED.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.26

News Sentiment

Canopy Growth has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Canopy Growth this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for WEED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Canopy Growth to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Canopy Growth insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$475,558.00 in company stock.

Percentage Held by Insiders

Only 0.27% of the stock of Canopy Growth is held by insiders.

Percentage Held by Institutions

Only 9.47% of the stock of Canopy Growth is held by institutions.

WEED Stock Analysis - Frequently Asked Questions

How have WEED shares performed this year?

Canopy Growth's stock was trading at C$6.76 at the start of the year. Since then, WEED shares have decreased by 6.1% and is now trading at C$6.35.
View the best growth stocks for 2024 here.

How do I buy shares of Canopy Growth?

Shares of WEED stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Canopy Growth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Canopy Growth investors own include Aurora Cannabis (ACB), Aphria (APHA), Auxly Cannabis Group (CBWTF), KushCo (KSHB) and Cronos Group (CRON).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: TSE:WEED
• CUSIP: N/A
• CIK: N/A
• Web: www.canopygrowth.com
• Phone: +1-613-5999600
• Fax: N/A
• Employees: 2,700
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$7.12
• High Stock Price Target: C$11.00
• Low Stock Price Target: C$3.50
• Potential Upside/Downside: +12.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($7.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.01
• Net Income: C$-602,300,000.00
• Net Margins: -259.94%
• Pretax Margin: N/A
• Return on Equity: -87.26%
• Return on Assets: -3.83%

Debt

• Debt-to-Equity Ratio: 117.00
• Current Ratio: 2.15
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: C$287.10 million
• Price / Sales: 1.88
• Cash Flow: C$3.89 per share
• Price / Cash Flow: 1.63
• Book Value: C$6.58 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 84,860,000
• Free Float: N/A
• Market Cap: C$538.86 million
• Optionable: Not Optionable
• Beta: 1.81